Every 10-Q that Atomera Incorporated (ATOM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ATOM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ATOM filings page.
Atomera Incorporated, an early-stage semiconductor technology licensing company, reported minimal revenue and continued losses for the quarter ended June 30, 2026. Revenue was $158 thousand for the quarter and $169 thousand for the first half of 2026, compared with $0 and $4 thousand in the prior-year periods. Net loss was $6,336 thousand for the quarter and $12,409 thousand year-to-date, with basic and diluted net loss per share of $0.17 and $0.34, respectively.
Operating expenses rose to $6,891 thousand in the quarter and $13,100 thousand for the first half, driven by higher research and development, general and administrative, and selling and marketing costs, including increased bonus accruals, stock-based compensation and patent-related legal expenses. Stock-based compensation totaled $3,147 thousand in the first half, and the company expanded its equity programs with new performance-based stock options and restricted stock units.
Liquidity strengthened through equity financing. As of June 30, 2026, Atomera held approximately $38.4 million in cash, cash equivalents and short-term investments and working capital of approximately $36.7 million. During the first half, it raised about $23.6 million via a registered direct offering of 5,000,000 shares at $5.00 per share and approximately $3.1 million through sales under a $50.0 million at-the-market facility. Net cash used in operating activities was $8,504 thousand for the first half of 2026, and management states that available capital is sufficient to fund current plans and obligations for at least 12 months.
Atomera Incorporated reported a wider first-quarter net loss while significantly strengthening its balance sheet. Revenue for the three months ended March 31, 2026 was about $11,000, up from $4,000 a year earlier, mostly from engineering services tied to MST wafer deliveries. Operating expenses rose to roughly $6.2 million, driven by higher research and development, general and administrative, and selling and marketing costs, leading to a net loss of about $6.1 million, similar on a per-share basis at $(0.17).
Cash, cash equivalents and short-term investments totaled approximately $41.1 million with working capital near $39.9 million, helped by equity financing. During the quarter Atomera raised about $23.6 million of net proceeds from a registered direct offering of 5,000,000 shares at $5.00 per share and approximately $3.1 million from selling around 1.3 million shares through its 2025 at-the-market program. Management believes existing capital can fund operations for at least 24 months while the company continues to develop and license its MST® semiconductor technology.
Atomera (ATOM) filed its Q3 2025 10‑Q, reporting minimal revenue while continuing to invest in R&D and operations. Revenue was $11,000 for the quarter (vs. $22,000 a year ago) and $15,000 year‑to‑date (vs. $112,000 a year ago). The company posted a net loss of $5.57 million for Q3 and $15.75 million for the nine months ended September 30, 2025, reflecting ongoing development and commercialization efforts.
Cash and cash equivalents were $20.3 million, with $18.1 million of working capital. Operating cash use was $11.6 million year‑to‑date. To support liquidity, Atomera utilized at‑the‑market equity programs, selling about 393,000 shares in Q3 2025 for roughly $2.0 million net proceeds and 742,000 shares year‑to‑date for about $5.2 million. After quarter‑end, it sold an additional 171,000 shares for approximately $836,000 net. Shares outstanding were 31,681,033 as of October 23, 2025.
Management concluded disclosure controls and procedures were not effective as of September 30, 2025 due to a previously identified material weakness, which they believe has been remediated and is undergoing testing.
Company and period: Atomera Incorporated (ATOM) Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.
Key financials: Cash and cash equivalents of $22.0 million and working capital of approximately $20.0 million as of June 30, 2025. Total assets were $24.1 million and total stockholders' equity was $21.3 million. Net loss was $(4.967) million for the three months ended June 30, 2025 and $(10.176) million for the six months ended June 30, 2025. Revenue was minimal: approximately $0 for the three months and $4,000 for the six months. Operating expenses for Q2 were $5.193 million (R&D $3.004M; G&A $2.048M; S&M $0.141M).
Liquidity and corporate actions: Management states available funds are sufficient to fund operations for at least 12 months from issuance date. The company generated net proceeds of approximately $3.2 million from ATM sales during the six-month period and approximately $792,000 in Q2; subsequent to period end it raised ~$2.0 million via the ATM. The company disclosed a previously-identified material weakness in internal control over journal entry review and is implementing enhanced controls.